Last viewed:
STVN
Prices are updated after-hours
STVN
|
$27.84
4.9%
120K
|
(0.0% 1d)
(-15.5% 1m)
(-0.7% 1y)
(0.0% 2d)
(0.0% 3d)
(-8.0% 7d)
(-58.61%
volume)
Earnings Calendar:
Market Cap: $ 8,227,834,602
https://www.stevanatogroup.com/en/
Sec
Filling
|
Patents
| n/a employees
(IT) Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
diagnostics
add to watch list
Paper trade
email alert is off
Press-releases
Stevanato Group appoints Ugo Gay as Chief Operations Officer
Published: 2024-04-04
(Crawled : 12:30)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -11.8%
| O: -0.37%
H: 4.77%
C: 1.07%
group
Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares
Published: 2024-03-22
(Crawled : 08:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -6.25%
| O: -0.74%
H: 11.67%
C: 10.36%
MS
|
News
0
d
|
$93.71
1.76%
2.2M
|
Finance
| -1.4%
| O: 0.13%
H: 0.36%
C: -1.68%
group
offering
Stevanato Group Reports Third Quarter 2023 Financial Results
Published: 2023-10-31
(Crawled : 12:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -2.96%
| O: -3.47%
H: 8.5%
C: 5.87%
group
financial
results
Stevanato Group Reports Second Quarter 2023 Financial Results
Published: 2023-07-28
(Crawled : 15:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -12.87%
| O: -1.08%
H: 5.16%
C: 3.45%
group
financial
results
Stevanato Group to Report Second Quarter 2023 Financial Results on July 28, 2023
Published: 2023-07-14
(Crawled : 23:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -17.06%
| O: -0.94%
H: 0.91%
C: -0.41%
report
group
financial
results
Stevanato Group Reports First Quarter 2023 Financial Results
Published: 2023-05-04
(Crawled : 18:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -4.46%
| O: -6.41%
H: 8.27%
C: 3.27%
group
financial
results
Stevanato Group to Present at BofA Securities Healthcare Conference
Published: 2023-05-02
(Crawled : 12:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| -2.78%
| O: -0.29%
H: 1.76%
C: 0.96%
conference
group
Stevanato Group Collaborates with Recipharm to Develop and Manufacture Pre-fillable Syringes for Use in a New Soft Mist Inhaler for the Inhalation of Sensitive Biological Products
Published: 2023-03-16
(Crawled : 14:20)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| 14.79%
| O: -1.82%
H: 5.81%
C: 4.63%
group
Stevanato Group Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Published: 2023-03-02
(Crawled : 14:00)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| 18.85%
| O: 3.0%
H: 6.39%
C: 3.09%
year
financial
results
group
Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma
Published: 2023-01-24
(Crawled : 15:20)
- biospace.com/
STVN
|
$27.84
4.9%
120K
|
| 28.77%
| O: -1.89%
H: 2.37%
C: 0.49%
pharma
group
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount